Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb 8:2:76-80.
doi: 10.7150/jca.2.76.

Patients with localised prostate cancer (t1 - t2) show improved overall long-term survival compared to the normal population

Michael J Mathers  1 , Stephan Roth, Monika Klinkhammer-Schalke, Michael Gerken, Ferdinand Hofstaedter, Stefan Wilm, Theodor Klotz
Affiliations

Patients with localised prostate cancer (t1 - t2) show improved overall long-term survival compared to the normal population

Michael J Mathers et al. J Cancer. .

Abstract

Background: Little information is available on the long-term outcomes of patients with localised prostate cancer.

Objective: To examine the long-term survival of patients with localised prostate gland carcinoma T1 - T2, N0, M0 (UICC stage I and II) compared to the normal population.

Design: Retrospective cohort.

Setting: Regensburg, Germany.

Participants: Data on 2121 patients with histologically-confirmed, localised prostate cancer diagnosed between 1998 and 2007 were extracted from the cancer registry of the tumour centre in Regensburg, Germany.

Measurements: Overall survival rate in the patient cohort was estimated and compared to the expected survival rate of a comparable group in the general population derived from the official life-tables of Germany stratified by age, sex and calendar year.

Results: Ten years after diagnosis, patients with stage I and II localised prostate gland carcinoma had an approximately 10% increase in survival compared to the normal male population (Relative Survival = 110.7%, 95%-CI 106.6 - 114.8%).

Limitations: We did not examine the effect of cancer treatment or cancer aggressiveness on the overall survival of patients. We did not assess the incidence of subsequent non-primary cancers in our patient population or how this incidence affects the patients' follow-up care and survival.

Conclusions: Patients with stage I+II localised prostate gland carcinoma have improved survival compared with the normal male population. This finding cannot be explained solely by the administration of prostate carcinoma treatments, suggesting that men who participate in PSA screening may have better overall health behaviors and care than men who do not participate in screening. Future research should examine how treatment choice, especially an "active surveillance" approach to care, affects survival in these patients more than ten years after diagnosis.

Keywords: PSA; health status; outcomes research; prostate cancer; social gradient of prevention.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors have declared that no conflict of interest exists.

Figures

Figure 1
Figure 1
Relative survival rates for the prostate cancer stage I+II, III and IV patient cohort.
See this image and copyright information in PMC

References

    1. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute, Bethesda, MD. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK; http://seer.cancer.gov/csr/1975_2006/
    1. Schröder FH, Hugosson J, Roobol MJ. et al.Screening and Prostate-Cancer Mortality in a Randomized European Study. N Engl J Med. 2009;360:1320–1328. - PubMed
    1. Borre M, Nerstrøm B, Overgaard J. The natural history of prostate carcinoma based on a Danish cancer population treated with no intent to cure. Cancer. 1997;80:917–928. - PubMed
    1. Catalona WJ, Smith DS, Ratliff TL. et al.Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156–61. - PubMed
    1. DGU. S3-Leitlinie Prostatakarzinom, Version 1,0. DGU. 2009.